You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION: There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CD4+ and CD8+ T cells with potent lytic activity. To stimulate the breadth, potency, and rate of response required, Profectus Biosciences intends to utilize its platform technologies based on electroporation of DNA vaccines combined with genetic a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Spiral Countercurrent Chromatography for High-throughput Natural Product Purifica

    SBC: CC Biotech LLC            Topic: NCCIH

    DESCRIPTION (provided by applicant): Recent advances in countercurrent chromatography (CCC) have created novel spiral-design separation columns that hold a very high stationary phase of all the solvent systems, such that now all molecules of any size and water solubility can be successfully separated in high-speed countercurrent chromatography. With spiral CCC there is inherent versatility, more t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Real-time qPCR assay for detection of ALT associated telomeric C-circle DNA in bl

    SBC: Capital Biosciences, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The overall goal of the proposed project is to investigate the feasibility of employing real-time qPCR method for detection of telomeric C-circle DNA in peripheral blood of patients with cancers that utilize Alternative Lengthening of Telomeres (ALT) as their Telomere length Maintenance Mechanism (TMM). Telomeric C-Circle DNA has been demonstrated to be specif ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Biomarker Breast Pap Test

    SBC: SILBIOTECH, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I research proposal is to investigate the feasibility of developing a novel Biomarker Breast PapTest for screening Nipple Aspirate Fluid (NAF) and detecting breast cancers at the tumor-in-formation stage before mammographically detectable tumors are developed. Although there is a slight decline in deaths from breast cancer in recent years, it conti ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Correcting Aberrant Splicing of the Human CD22 Gene

    SBC: RETROTHERAPY, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): B-precursor acute lymphoblastic leukemia (BPL) is the most common form of cancer in children and adolescents. This project addresses an urgent and unmet need for the treatment of aggressive, treatment refractory BPL. Two recent studies have found a deletion of CD22 exon 12 (CD22?E12) in primary leukemic cells in the vast majority of pediatric patients with poor ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Building an open-source cloud-based computational platform to improve data access

    SBC: BIODATOMICS, LLC            Topic: NIDA

    We propose to develop a novel, cost-effective, cloud-based data and analytics platform that will provide efficient data storage solutions and enhanced analytics, annotation and reporting capabilities for supporting and accelerating clinical and molecular research in the treatment of substance use disorders (SUD). This open source platform, which leverages existing BioDX technology, will provide a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Engineered Neurotensin Fragments Targeting Neuropathic Pain

    SBC: JT Pharmaceuticals, Inc.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Cerberus-LNR: A Tethered Lightfield 3D Endoscope for Advanced Minimally Invasive

    SBC: XIGEN, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The primary objective of this SBIR is to develop and pre-clinically evaluate a novel lightfield 3D endoscope, dubbed Cerberus-LNR, specially designed for laparoendoscopic single-site surgery (LESS), natural orifice translumenal endoscopic surgery (NOTES), and robotic LESS (R-LESS) (hereafter LNR) procedures. The miniature Cerberus-LNR lightfield 3D endoscope co ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a lasmiditan analogue for treatment of acute kidney injury

    SBC: Mitohealth, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government